NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: Anti-clotting Medication Effectiveness After Stent Placement in Diabetes Patients
TL;DR
Prasugrel offers better outcomes than ticagrelor for diabetic patients with stents, providing a clinical advantage in reducing heart attacks, strokes, and death rates.
The TUXEDO-2 study compared prasugrel and ticagrelor in 1,800 diabetic patients with stents, finding prasugrel had lower rates of heart attack, stroke, bleeding, and death.
This research helps improve treatment for diabetic patients with heart stents, potentially saving lives and reducing complications through better medication selection.
In a surprising finding, prasugrel outperformed ticagrelor in diabetic stent patients, challenging the assumption that these antiplatelet medications are interchangeable.
Found this article helpful?
Share it with your network and spread the knowledge!
This study compares the effectiveness of two antiplatelet medications, ticagrelor and prasugrel, in preventing complications like heart attacks, strokes, bleeding, and death in patients with Type 1 or Type 2 diabetes who have received drug-eluting stents.
The findings suggest these two commonly used medications may not be interchangeable for diabetes patients, and choosing the right antiplatelet therapy could significantly impact patient outcomes after stent placement.
The study found that prasugrel showed better outcomes, with a composite rate of heart attack, stroke, bleeding complications or death of 14.23% compared to 16.57% in the ticagrelor group.
The TUXEDO-2 study involved 1,800 adults in India with Type 1 or Type 2 diabetes and multivessel disease who received drug-eluting stents, led by Dr. Sripal Bangalore from NYU Grossman School of Medicine.
The preliminary findings were presented on November 10, 2025, at the American Heart Association's Scientific Sessions 2025 in New Orleans.
Both ticagrelor and prasugrel are P2Y12 inhibitors that prevent platelets from clumping together and forming clots in stents, helping to keep arteries open and free of blockages.
Patients should be aware that prasugrel may potentially be the better choice for preventing complications, and they should discuss medication options with their healthcare provider rather than assuming these drugs are interchangeable.
This is a preliminary research abstract presented at a scientific meeting that has not yet been peer-reviewed, and the findings should be considered preliminary until published as a full manuscript in a peer-reviewed journal.
All patients received drug-eluting stents, which are coated with medication to help reduce the risk of re-narrowing of the stents after implantation.
Curated from NewMediaWire
